A man who had long experienced aphantasia (the inability to form voluntary mental images) reported modest but sustained improvements in his visual imagery after a single dose of ayahuasca, a botanical hallucinogen rich in DMT. The improvements were attributed to possible biological and psychological processes, including stimulation of cortical 5-HT2A receptors, increased activity in the visual cortex, and resolution of psychological trauma from a difficult relationship with his father. The case suggests that 5-HT2A agonists like ayahuasca may offer a path to explore treatments for aphantasia, though further trials are needed.
A survey of 564 natural psychoactive drug (NPD) users from 52 countries found that the typical user is a well-educated adult who uses these substances sporadically. Psilocybe mushrooms (88.5%) and ayahuasca (51%) were the most used. Users reported positive life influences and good mental health. The authors argue that NPDs differ from synthetic new psychoactive substances (NPSs) in safety and use patterns, and should not be legally classified together with NPSs.